Does initial dual oral combination therapy improve symptoms, exercise capacity, haemodynamics, and survival compared to oral monotherapy in incident pulmonary arterial hypertension patients with cardiovascular comorbidities?
Initial dual oral combination therapy improves symptoms and haemodynamics without increasing discontinuation rates compared to monotherapy in PAH patients with cardiovascular comorbidities, challenging current guidelines that recommend monotherapy.
Background European guidelines recommend initial monotherapy in pulmonary arterial hypertension patients with cardiovascular comorbidities based on the limited evidence for combination therapy in this growing population. Methods A retrospective analysis was conducted on incident pulmonary arterial hypertension patients enrolled in the French Pulmonary Hypertension Registry between 2009 and 2020. Propensity score matching was used to investigate initial dual oral combination therapy versus oral monotherapy in patients with at least one cardiovascular comorbidity ( i.e. hypertension, obesity, diabetes and coronary artery disease). Results Of the 1784 patients identified, 1088 had at least one cardiovascular comorbidity, including 20% with three or comorbidities. In the propensity score-matched population (n=708), the majority of patients were female, with idiopathic/heritable/drug-induced pulmonary arterial hypertension at intermediate 1-year mortality risk. At first follow-up, initial dual therapy led to larger improvements in symptoms, exercise capacity, haemodynamic parameters and risk status than initial monotherapy, with no differences in long‑term survival. Treatment discontinuation was observed in 23% of patients initiated on dual therapy and 24% of those initiated on monotherapy. Conclusions Initial dual oral combination therapy may be beneficial and well-tolerated in most pulmonary arterial hypertension patients with cardiovascular comorbidities.
Boucly et al. (Thu,) studied this question.